Last $14.11 USD
Change Today +0.19 / 1.36%
Volume 213.7K
VNDA On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 2:03 PM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

vanda pharmaceuticals inc (VNDA) Snapshot

Open
$13.90
Previous Close
$13.92
Day High
$14.29
Day Low
$13.82
52 Week High
03/24/14 - $19.25
52 Week Low
11/8/13 - $5.70
Market Cap
476.8M
Average Volume 10 Days
439.2K
EPS TTM
$-1.30
Shares Outstanding
33.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VANDA PHARMACEUTICALS INC (VNDA)

vanda pharmaceuticals inc (VNDA) Related Businessweek News

No Related Businessweek News Found

vanda pharmaceuticals inc (VNDA) Details

Vanda Pharmaceuticals Inc., a biopharmaceutical company, is engaged in the development and commercialization of pharmaceutical products. Its product portfolio includes HETLIOZ, a product for the treatment of Non-24-Hour Sleep-Wake Disorder; Fanapt, a product for the treatment of schizophrenia; and VLY-686, a small molecule neurokinin-1 receptor antagonist. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

53 Employees
Last Reported Date: 02/25/14
Founded in 2002

vanda pharmaceuticals inc (VNDA) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $515.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $315.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $279.8K
Compensation as of Fiscal Year 2013.

vanda pharmaceuticals inc (VNDA) Key Developments

Vanda Pharmaceuticals Inc. Announces Marketing Authorization Application for Oral HETLIOZTM (tasimelteon) Capsules

Vanda Pharmaceuticals Inc. announced that its Marketing Authorization Application for oral HETLIOZTM (tasimelteon) capsules has been accepted for evaluation by the European Medicines Agency (EMA) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ™ has been granted orphan drug designation for the treatment of Non-24 in blind people with no light perception from the European Commission. HETLIOZ™ was approved by the FDA in January 2014 and is available through specialty pharmacies in the U.S.

Vanda Pharmaceuticals, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 10:30 AM

Vanda Pharmaceuticals, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 10:30 AM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Mihael H. Polymeropoulos, Founder, Chief Executive Officer, President and Director.

Vanda Pharmaceuticals, Inc. Presents at JMP Securities Healthcare Conference, Jun-24-2014 09:00 AM

Vanda Pharmaceuticals, Inc. Presents at JMP Securities Healthcare Conference, Jun-24-2014 09:00 AM. Venue: The Westin New York Grand Central, 212 East 42nd Street, New York, NY 10017, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VNDA:US $14.11 USD +0.19

VNDA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,392 GBp -32.50
Eli Lilly & Co $63.53 USD -0.84
Sanofi €75.98 EUR -1.34
Sumitomo Dainippon Pharma Co Ltd ¥1,237 JPY +9.00
Transcept Pharmaceuticals Inc $2.26 USD -0.02
View Industry Companies
 

Industry Analysis

VNDA

Industry Average

Valuation VNDA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.5x
Price/Book 22.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VANDA PHARMACEUTICALS INC, please visit www.vandapharmaceuticals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.